Badanie z GSK4527363 u zdrowych uczestników, uczestników z toczniem rumieniowatym układowym (TRU), zdrowych uczestników pochodzenia chińskiego i japońskiego i uczestników ze śródmiąższową chorobą płuc związaną z chorobą tkanki łącznej (CTD-ILD).

Kryteria wyłączenia kto nie może wziąć udziału (49)

1. For Part A and Part C (Healthy Participants):
2. History or presence or cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders
3. A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug
4. Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks before dosing
5. Symptomatic herpes zoster within 3 months prior to screening
6. Have a history of malignancy, or a strong family history of malignancies related to immunosuppression
7. Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions
8. Abnormal blood pressure
9. Evidence of active or latent Tuberculosis (TB)
10. Alanine transaminase (ALT) >=1.1* Upper limit of normal (ULN)
11. Total bilirubin >1.0*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >=1.5*ULN as long as direct bilirubin is less than or equal to (<=)1.5*ULN
12. Presence of Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
13. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
14. Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
15. Positive Human immunodeficiency virus (HIV) antibody test at screening
16. Prior medical history of anaphylaxis
17. QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec)
18. Live vaccine(s) within 30 days before the dosing day or plans to receive such vaccines during the study For Part B (SLE participants):
19. Any acute, severe lupus related flare during the Screening Period that needs immediate treatment
20. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk
21. Have an acute or chronic infection requiring management as follows:
22. i. Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria ii. A serious infection requiring treatment with antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed
23. Evidence of active or latent TB
24. Confirmed Progressive Multifocal Leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms
25. ALT >2*ULN
26. Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN
27. Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
28. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
29. Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
30. History or positive test at Screening for HIV
31. QTcF >450 msec
32. Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, Cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
33. Live or live-attenuated vaccine(s) within 30 days prior to Screening For Part D Participants:
34. A diagnosis of: ILD other than CTD-ILD and/or SLE
35. FVC <= 45% predicted at Screening Pulmonary arterial hypertension, as determined by the Investigator, prior to Day 1
36. Major surgery (including joint surgery) within 3 months prior to Screening or planned during the duration of the study
37. Previous or planned major organ transplant (e.g. heart, lung, kidney, liver) or bone marrow transplant (e.g. autologous stem cell transplant)
38. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to CTD-ILD (i.e., cardiovascular, metabolic, hematologic, GI, hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) which, in the opinion of the PI, could confound the results of the clinical study or put the participant at undue risk
39. Have an acute or chronic infection including requiring management
40. Evidence of active or latent TB
41. Confirmed PML or unexplained new-onset or deteriorating neurologic signs and symptoms
42. ALT >2*ULN
43. Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN
44. Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
45. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
46. Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
47. History or positive test at Screening for HIV
48. Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, CIN or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
49. Live or live-attenuated vaccine(s) within 30 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study